AUPH | Aurinia Pharmaceuticals Inc.

Index- P/E- EPS (ttm)-0.68 Insider Own0.10% Shs Outstand142.64M Perf Week15.36%
Market Cap1.43B Forward P/E- EPS next Y-0.42 Insider Trans-32.80% Shs Float132.88M Perf Month-9.69%
Income-96.80M PEG- EPS next Q-0.18 Inst Own40.50% Short Float / Ratio11.68% / 5.07 Perf Quarter15.49%
Sales146.80M P/S9.72 EPS this Y45.50% Inst Trans9.51% Short Interest15.52M Perf Half Y104.71%
Book/sh2.74 P/B3.81 EPS next Y38.20% ROA-20.40% Target Price16.00 Perf Year-8.26%
Cash/sh2.64 P/C3.95 EPS next 5Y- ROE-23.60% 52W Range4.07 - 13.41 Perf YTD141.67%
Dividend- P/FCF- EPS past 5Y3.70% ROI-27.90% 52W High-22.18% Beta1.18
Dividend %- Quick Ratio9.30 Sales past 5Y216.80% Gross Margin96.00% 52W Low156.51% ATR0.60
Employees300 Current Ratio10.10 Sales Q/Q59.30% Oper. Margin-70.30% RSI (14)51.93 Volatility5.73% 5.50%
OptionableYes Debt/Eq0.00 EPS Q/Q30.80% Profit Margin-65.90% Rel Volume0.80 Prev Close9.91
ShortableYes LT Debt/Eq0.00 EarningsMay 04 BMO Payout- Avg Volume3.06M Price10.44
Recom2.10 SMA200.78% SMA50-2.25% SMA20029.52% Volume2,463,768 Change5.35%
Date Action Analyst Rating Change Price Target Change
Nov-04-22Downgrade Oppenheimer Outperform → Perform
May-05-22Resumed Cantor Fitzgerald Overweight $34 → $25
Dec-10-21Upgrade Oppenheimer Perform → Outperform $33 → $31
Oct-28-21Downgrade Oppenheimer Outperform → Perform $32
Jan-25-21Reiterated H.C. Wainwright Buy $30 → $35
Nov-03-20Reiterated H.C. Wainwright Buy $34 → $28
Jun-17-20Initiated BTIG Research Buy $20
May-05-20Initiated Cowen Outperform
Jan-10-20Initiated Jefferies Buy $27
Dec-16-19Reiterated H.C. Wainwright Buy $25 → $32
May-08-15Initiated MLV & Co Buy $9
Jun-06-23 08:11AM
Jun-01-23 09:00AM
May-26-23 05:16PM
May-23-23 06:56AM
May-17-23 12:14PM
12:00PM Loading…
May-11-23 12:00PM
May-09-23 06:02AM
May-04-23 07:15AM
May-03-23 07:51AM
May-02-23 04:36PM
Apr-28-23 06:30AM
11:30AM Loading…
Apr-26-23 11:30AM
Apr-25-23 11:00AM
Apr-24-23 05:10PM
Apr-12-23 12:34PM
Apr-11-23 02:41PM
Apr-05-23 06:30AM
Apr-04-23 06:42AM
Apr-03-23 04:00PM
Mar-27-23 04:52AM
Mar-09-23 09:17AM
Mar-08-23 05:09AM
Mar-06-23 04:00PM
07:15AM Loading…
Feb-28-23 07:15AM
Feb-24-23 06:00AM
Feb-23-23 07:46AM
Feb-22-23 10:00AM
Feb-21-23 10:00AM
Feb-19-23 07:30AM
Feb-17-23 05:42AM
Feb-07-23 04:00PM
Feb-06-23 04:00PM
Jan-27-23 06:40PM
Jan-25-23 01:00PM
Jan-24-23 04:00PM
Jan-16-23 05:39AM
Jan-06-23 04:49PM
Jan-04-23 04:05PM
Jan-03-23 04:55PM
Dec-05-22 04:05PM
Nov-30-22 04:05PM
Nov-08-22 08:39AM
Nov-04-22 12:12PM
Nov-03-22 07:25AM
Oct-30-22 10:45AM
Oct-28-22 05:30PM
Oct-27-22 12:00PM
Oct-21-22 09:12AM
Oct-09-22 09:40AM
Oct-03-22 04:05PM
Sep-21-22 01:41PM
Sep-20-22 04:05PM
Sep-19-22 11:15AM
Sep-05-22 06:22AM
Aug-08-22 11:27AM
Aug-04-22 11:58AM
Aug-01-22 04:05PM
Jul-27-22 12:22PM
Jul-26-22 02:00PM
Jul-25-22 04:07PM
Jul-22-22 06:05AM
Jul-15-22 04:10PM
Jul-14-22 04:10PM
Jul-05-22 03:17AM
Jul-01-22 04:46PM
Jun-06-22 04:05PM
Jun-03-22 07:05AM
May-20-22 12:07PM
May-16-22 07:17AM
May-10-22 07:15AM
May-06-22 04:05PM
May-02-22 04:05PM
Apr-28-22 03:02PM
Apr-19-22 07:10AM
Apr-04-22 04:11PM
Mar-04-22 04:37AM
Mar-03-22 04:31PM
Mar-01-22 04:49AM
Feb-28-22 04:28PM
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jayne David R.W.DirectorMay 23Sale11.268,73398,33449,310May 23 05:19 PM
MacKay-Dunn R. HectorDirectorMay 23Sale11.264,81854,25124,225May 23 05:16 PM
Leversage JillDirectorMay 23Sale11.264,81554,21718,528May 23 05:14 PM
Billen DanielDirectorMay 23Sale11.264,65052,35933,393May 23 05:17 PM
Hagan Joseph PDirectorMay 19Sale10.582722,87811,961May 23 05:18 PM
MILNE GEORGE M JRDirectorMar 02Buy8.9120,000178,28470,000Mar 06 04:29 PM
Greenleaf PeterChief Executive OfficerMar 02Sale8.9432,750292,785982,968Mar 06 04:27 PM
Robertson Stephen P.EVP, General CounselMar 02Sale8.9419,402173,454303,364Mar 06 04:29 PM
Miller Joseph MChief Financial OfficerMar 02Sale8.9411,296100,986331,214Mar 06 04:29 PM
Donley Matthew MaxwellEx VP, Internal OperationsNov 21Buy4.6610,00046,60027,927Nov 23 04:04 PM
Habig Scott MichaelChief Commercial OfficerNov 09Buy5.015,00025,0755,000Nov 14 04:31 PM
Martin Michael RobertChief Business OfficerNov 07Buy5.1630,000154,80089,512Nov 09 04:05 PM